ABSTRACT
Background Higher circulating polyunsaturated fatty acids (PUFAs), especially omega-3 ones, have been linked to a better prognosis in patients of coronavirus disease 2019 (COVID-19). However, the effects and causality of pre-infection PUFA levels remain unclear.
Objective To investigate the observational and causal associations of circulating PUFAs with COVID-19 susceptibility and severity.
Design We first performed a prospective cohort study in UK Biobank, with 20,626 controls who were tested negative and 4,101 COVID-19 patients, including 970 hospitalized ones. Plasma PUFAs at baseline were measured by nuclear magnetic resonance, including total PUFAs, omega-3 PUFAs, omega-6 PUFAs, docosahexaenoic acid (DHA), linoleic acid (LA), and the omega-6/omega-3 ratio. Moreover, bidirectional two-sample Mendelian randomization (MR) analyses were performed to examine the causal associations of eight individual PUFAs, measured in either plasma or red blood cells, with COVID-19 susceptibility and severity using summary statistics from existing genome-wide association studies.
Results In the observational association analysis, total PUFAs, omega-3 PUFAs, omega-6 PUFAs, DHA, and LA were associated with a lower risk of severe COVID-19. Omega-3 PUFAs and DHA were also associated with a lower risk of testing positive for COVID-19. The omega-6/omega-3 ratio was positively associated with risks of both susceptibility and severity. The forward MR analysis indicated that arachidonic acid (AA) and docosapentaenoic acid (DPA-n3) might be causally associated with a lower risk of severe COVID-19, with OR (95% CI) per one SD increase in the plasma level as 0.96 (0.94, 0.99) and 0.89 (0.81, 0.99), respectively. The reverse MR analysis did not support any causal effect of COVID-19 on PUFAs.
Conclusions Our observational analysis supported that higher circulating PUFAs, either omega-3 or omega-6, are protective against severe COVID-19, while omega-3 PUFAs, especially DHA, were also associated with reducing COVID-19 susceptibility. Our MR analysis further supported causal associations of AA and DPA-n3 with a lower risk of severe COVID-19.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the University of Georgia Research Foundation and by the National Institute of General Medical Sciences of the National Institutes of Health under Award Number R35GM143060. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the University of Georgia.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The usage of individual-level data for this study was approved by the University of Georgia Institutional Review Board and the UK Biobank (application no. 48818).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Abbreviations used
- COVID-19
- coronavirus disease 2019
- SARS-CoV-2
- severe acute respiratory syndrome coronavirus 2
- PUFAs
- polyunsaturated fatty acids
- LA
- linoleic acid
- EPA
- eicosapentaenoic acid
- DHA
- docosahexaenoic acid
- RBC
- red blood cell
- AA
- arachidonic acid
- MR
- Mendelian randomization
- BMI
- body mass index
- GWAS
- genome-wide association studies
- HGI
- COVID-19 Host Genetics Initiative
- FHS
- Framingham Heart Study
- STROBE
- strengthening the reporting of observational studies in epidemiology
- STROBE-MR
- strengthening the reporting of Mendelian randomization studies
- ALA
- α-Linolenic acid
- DPA-n3
- docosapentaenoic acid
- GLA
- γ-Linoleic acid
- DGLA
- dihomo-γ-linoleic acid
- DTA
- docosatetraenoic acid
- NMR
- nuclear magnetic resonance
- SD
- standard deviation
- SNPs
- single nucleotide polymorphisms
- LD
- linkage disequilibrium
- OR
- odds ratio
- IVW
- inverse variance-weighted
- WM
- weighted median
- CI
- confidence interval
- PGs
- prostaglandins
- HCoV-229E
- human coronavirus 229E
- MERS-CoV
- Middle East respiratory syndrome coronavirus.
Paper in collection COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos